Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.
Objective To develop prediction models for short-term outcomes following a first acute myocardial infarction (AMI) event (index) or for past AMI events (prevalent) in a national primary care cohort.
XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...
Braze (Nasdaq: BRZE), the leading customer engagement platform that empowers brands to Be Absolutely Engaging™, today ...
Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...
Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy December ...
Wave Life Sciences Ltd. ( WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity December 8, 2025 8:30 AM EST ...
The Healthy @Reader's Digest on MSN
This is the ideal blood pressure that prevents heart disease, says new study
Blood pressure guidelines vary from country to country, but new insights from Korea reinforce a universal systolic blood ...
On October 31, 2025, the Centers for Medicare & Medicaid Services (CMS) finalized the Ambulatory Specialty Model (ASM) in the CY 2026 ...
Among individuals in Sweden receiving second-generation drug-eluting stents, those with diabetes, particularly type 1 ...
Distributors are leaving massive amounts of cash trapped in operations. This article breaks down where working capital gets ...
User engagement in a digital weight-loss program yielded better results in participants taking GLP-1 receptor agonists than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback